Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C3165106
Disease: Infiltrating duct carcinoma of female breast
Infiltrating duct carcinoma of female breast 		0.300 GeneticVariation disease UNIPROT
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.100 GeneticVariation disease GWASDB Genome-wide association study identifies five new schizophrenia loci. 21926974 2011
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.050 AlteredExpression disease BEFREE Further study showed that SMG-1 expression was exactly associated with tumor differentiation and clinical stage in HCC. 24700316 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.050 Biomarker disease BEFREE More important, SMG1 knockdown reverses the suppressive function of MAGI2-AS3 in HCC cell processes. 30924168 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.050 Biomarker disease BEFREE The inhibition of SMG-1 reduced sorafenib sensitivity in the studied HCC cell lines. 25017961 2014
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.050 AlteredExpression disease BEFREE In vitro studies show that low oxygen increases hepatocellular ATX expression and transcriptome analysis showed a positive correlation between ATX mRNA levels and hypoxia gene score in HCC tumour tissue associated with HCV and other aetiologies. 28126468 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.050 AlteredExpression disease BEFREE ATX gene was found to be overexpressed in some HCC and correlated with HCC development and metastases. 11593532 1999
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.040 Biomarker disease BEFREE The decreased MARVELD1 level in lung cancer reduces NMD efficiency through diminishing the association between NMD complex component UPF1/SMG1 and premature termination codons containing mRNA (PTC-mRNA). 25520033 2014
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.040 Biomarker disease BEFREE Here we use both preclinical models of lung cancer and clinical samples (from patients and healthy controls) to investigate the expression levels, activity, and biological role of the above components of the ATX/LPA axis in lung cancer. 29724718 2018
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.040 GeneticVariation disease BEFREE In mice, total loss of SMG1 is embryonic lethal and loss of a single allele results in an increased rate of cancer development, particularly haematopoietic cancers and lung cancer. 31565865 2019
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.040 AlteredExpression disease BEFREE We compared the anti-tumor activity of ATX-s10-PDT against lung cancer cell lines SBC-3 and SBC-3/VEGF, the latter overexpressing VEGF; there was no significant difference in the sensitivity to the PDT between the two cell lines as assessed by clonogenic assay. 17671719 2007
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 Biomarker disease BEFREE The decreased MARVELD1 level in lung cancer reduces NMD efficiency through diminishing the association between NMD complex component UPF1/SMG1 and premature termination codons containing mRNA (PTC-mRNA). 25520033 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 GeneticVariation disease BEFREE In mice, total loss of SMG1 is embryonic lethal and loss of a single allele results in an increased rate of cancer development, particularly haematopoietic cancers and lung cancer. 31565865 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 Biomarker disease BEFREE Here we use both preclinical models of lung cancer and clinical samples (from patients and healthy controls) to investigate the expression levels, activity, and biological role of the above components of the ATX/LPA axis in lung cancer. 29724718 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.040 AlteredExpression disease BEFREE We compared the anti-tumor activity of ATX-s10-PDT against lung cancer cell lines SBC-3 and SBC-3/VEGF, the latter overexpressing VEGF; there was no significant difference in the sensitivity to the PDT between the two cell lines as assessed by clonogenic assay. 17671719 2007
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.040 GeneticVariation disease BEFREE In mice, total loss of SMG1 is embryonic lethal and loss of a single allele results in an increased rate of cancer development, particularly haematopoietic cancers and lung cancer. 31565865 2019
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.040 Biomarker disease BEFREE Here we use both preclinical models of lung cancer and clinical samples (from patients and healthy controls) to investigate the expression levels, activity, and biological role of the above components of the ATX/LPA axis in lung cancer. 29724718 2018
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.040 AlteredExpression disease BEFREE We compared the anti-tumor activity of ATX-s10-PDT against lung cancer cell lines SBC-3 and SBC-3/VEGF, the latter overexpressing VEGF; there was no significant difference in the sensitivity to the PDT between the two cell lines as assessed by clonogenic assay. 17671719 2007
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.040 Biomarker disease BEFREE The decreased MARVELD1 level in lung cancer reduces NMD efficiency through diminishing the association between NMD complex component UPF1/SMG1 and premature termination codons containing mRNA (PTC-mRNA). 25520033 2014
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.030 Biomarker disease BEFREE Serum ATX as a novel biomarker for breast cancer. 30921203 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.030 Biomarker disease BEFREE Thus, ATX and LPA receptors can contribute to the initiation and progression of breast cancer. 19477432 2009
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.030 Biomarker disease BEFREE In this work, we studied the effects of an ATX inhibitor, GLPG1690, which is in Phase 3 clinical trials for idiopathic pulmonary fibrosis, on responses to radiotherapy and chemotherapy in a syngeneic orthotopic mouse model of breast cancer. 31548293 2020
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.030 Biomarker disease BEFREE Serum ATX as a novel biomarker for breast cancer. 30921203 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.030 Biomarker disease BEFREE Thus, ATX and LPA receptors can contribute to the initiation and progression of breast cancer. 19477432 2009
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.030 Biomarker disease BEFREE In this work, we studied the effects of an ATX inhibitor, GLPG1690, which is in Phase 3 clinical trials for idiopathic pulmonary fibrosis, on responses to radiotherapy and chemotherapy in a syngeneic orthotopic mouse model of breast cancer. 31548293 2020